CD28-ARS2 Axis Drives PKM Splicing and Metabolic Flexibility in CD8+ T Cells

Study Background and Research Question

Metabolic reprogramming is a hallmark of activated CD8+ T cells, enabling their proliferation and acquisition of effector properties necessary for antitumor responses. While the shift toward aerobic glycolysis (the Warburg effect) is well documented in both immune and cancer cells, the molecular mechanisms that confer metabolic flexibility in T cells, particularly at the posttranscriptional level, remain incompletely understood. Notably, the expression and splicing of glycolytic enzymes such as pyruvate kinase M (PKM) are dynamically regulated in tumors, but how similar mechanisms operate in cytotoxic T lymphocytes (CTLs) is unresolved. The study by Holling et al. (Cellular & Molecular Immunology, 2024) addresses this gap by examining the role of the nuclear cap-binding complex adaptor protein ARS2 in alternative splicing and metabolic adaptation of CD8+ T cells following activation.

Key Innovation from the Reference Study

The central innovation of this work lies in the identification of a CD28-ARS2 signaling axis that directly impacts alternative splicing of the PKM gene, favoring the PKM2 isoform over PKM1. The authors demonstrate that CD28 costimulation, a canonical T cell activation signal, upregulates ARS2, which in turn coordinates the recruitment of splicing factors to pre-mRNAs. This axis regulates approximately one-third of the alternative splicing events induced during T cell activation, with a pronounced effect on the PKM1/PKM2 isoform balance. Importantly, this regulatory pathway operates independently of the classical PI3K signaling cascade, revealing a new dimension of posttranscriptional control in T cell immunometabolism (Holling et al., 2024).

Methods and Experimental Design Insights

The authors employed a series of genetic and biochemical approaches to dissect the CD28-ARS2 axis. Using primary murine CD8+ T cells and CRISPR/Cas9-mediated gene editing, they generated ARS2-deficient cells and monitored transcriptomic changes upon activation. RNA sequencing enabled quantification of alternative splicing events, while immunoblotting and qPCR validated isoform-specific expression of PKM. Functional assays, including metabolic flux analysis and effector cytokine measurement, were used to assess the impact on glycolytic capacity and antitumor potential. The independence from PI3K signaling was established via pharmacologic inhibition and downstream pathway interrogation.

Core Findings and Why They Matter

Holling et al. found that CD28-driven upregulation of ARS2 is crucial for the posttranscriptional landscape of activated CD8+ T cells. Specifically, ARS2 promotes recruitment of key splicing factors that suppress PKM1 and favor PKM2 isoform generation. PKM2, compared to PKM1, supports a metabolic profile that accumulates glycolytic intermediates, fueling anabolic processes and efficient interferon gamma (IFNγ) production. This metabolic flexibility is linked to enhanced antitumor effector functions, as demonstrated by improved cytotoxic responses in in vivo tumor models (reference study).

Notably, the splicing regulation by ARS2 does not require activation of the PI3K pathway, indicating that T cell costimulation reprograms metabolism through multiple, parallel routes. This finding adds nuance to our understanding of how T cell activation signals are integrated at both the transcriptional and posttranscriptional levels, with direct relevance to immunotherapy strategies that seek to exploit or enhance T cell metabolism.

Comparison with Existing Internal Articles

Recent internal resources, such as "Probenecid as a Translational Catalyst" and "Probenecid: Redefining Multidomain Modulation", contextualize the importance of modulating transporter and metabolic pathways in both oncology and neuroprotection. While these articles focus on Probenecid (4-(dipropylsulfamoyl)benzoic acid) as a tool for dissecting multidrug resistance and neuroprotection in cerebral ischemia/reperfusion injury, they also highlight the importance of immunometabolic reprogramming in experimental design. The current study provides a mechanistic blueprint for how T cell metabolic flexibility can be genetically and biochemically manipulated, offering complementary insights for researchers using Probenecid to probe multidrug resistance-associated proteins (MRPs) and study transporter-mediated effects on immune cell function. The intersection of alternative splicing, metabolic adaptation, and transporter regulation is therefore a promising area for translational research, as emphasized across these resources.

Limitations and Transferability

Although the study provides strong evidence for the role of ARS2 in regulating PKM isoform expression and metabolic flexibility, several limitations should be noted. Most experiments were performed in murine models, and while primary human CD8+ T cells share similar pathways, the extent of ARS2 regulation and PKM splicing may differ between species. Additionally, the focus was on acute T cell activation and short-term effector responses; the impact on T cell memory, exhaustion, or chronic stimulation in the tumor microenvironment remains to be elucidated. Transferability to clinical immunotherapy settings will require careful validation, particularly in heterogeneous human tumors where metabolic and splicing landscapes are more complex.

Protocol Parameters

• Genetic manipulation: Use CRISPR/Cas9 to generate ARS2-deficient CD8+ T cells for functional assays.
• T cell activation: Employ anti-CD3/CD28-coated beads or antibodies to induce robust costimulatory signaling and upregulate ARS2 expression.
• Alternative splicing analysis: Conduct RNA-seq within 24–48 hours post-activation to capture dynamic splicing events, focusing on PKM exon inclusion.
• Metabolic profiling: Implement Seahorse extracellular flux assays to measure glycolytic capacity and mitochondrial respiration in activated versus ARS2-deficient T cells.
• Effector function assessment: Quantify IFNγ, TNFα, and IL-2 production by ELISA or intracellular staining to link metabolic state to cytokine output.
• Pharmacologic pathway dissection: Apply PI3K inhibitors to confirm the independence of ARS2-mediated splicing from canonical metabolic signaling.

Research Support Resources

To experimentally dissect the interplay between metabolic flexibility, efflux transporters, and immune function, researchers may benefit from using chemical modulators such as Probenecid (SKU B2014). As a potent inhibitor of organic anion transporters, MRPs, and pannexin-1 channels, Probenecid can be employed to study multidrug resistance reversal in leukemia models or to probe transporter contributions to T cell metabolism and effector function. Detailed protocols and advanced applications are discussed in resources like "Probenecid: Applied Protocols for Neuroprotection & MDR Reversal". Probenecid is available from APExBIO as a solid or solution for research use, with handling and storage recommendations provided in the product information.